QCLS.US Q/C Technologies, Inc.

Technology Pharmaceuticals USA Stocks
0.3340 USD
Close of Nov 18, 2026
0.2800 8.17
Market cap
USD 2.74M
P/E
0.1x
P/B
0.16x
ROE
-72.8%
Dividend yield
2.84%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is QCLS.US undervalued?

Graham number

The Graham number of Q/C Technologies, Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Q/C Technologies, Inc. fundamental analysis

No fundamental analysis for Q/C Technologies, Inc. yet.

Q/C Technologies, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Q/C Technologies, Inc.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog …

Full company profile